Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Action Myanmar and MOCRU health teams identified a number of children with rickets in remote areas of Myanmar. MOCRU director Frank Smithuis presented the findings of clinical screening to the Minister of Health, alongside treatment results and a plan for a large survey to investigate the prevalence of vitamin D deficiency and its underlying causes.

Location of 158 children with rickets in the Naga region of Myanmar

After Medical Action Myanmar (MAM) / Myanmar-Oxford Clinical Research Unit (MOCRU) health teams had earlier found a number of children with characteristics of rickets in remote communities in north-west of Myanmar's Naga region on the Indian border, active screening in other villages in the region led to 182 children being identified with severe rickets.

A leg with rickets and its x-rayAs can be seen from the photo and the x-ray, the children, and some adults, have great difficulties walking, with some unable to walk at all. It seems that none had been diagnosed or treated earlier, possibly because their communities are extremely remote, only accessible after many hours walking.

Lab results indicated that the rickets was caused by vitamin D deficiency. Treatment with vitamin D and calcium was started immediately and follow up laboratory and X-ray investigations showed improved bone growth and bone remodelling.

After being informed of the findings, Minister of Health Dr Myint Htwe invited MAM and MOCRU to discuss the findings and local needs. On 31 May, at a follow up meeting organised by the Minister with national and regional health officials, and UN and NGO representatives, MOCRU Director Frank Smithuis presented the findings of clinical screening, patient investigations, treatment results and a plan to do a large survey in several villages in the region to investigate vitamin D deficiency prevalence and its underlying causes. The survey would include:    

  • The epidemiology and aetiology of rickets among children and pregnant women in Naga and other regions;
  • Local behaviours related to vitamin D deficiency and nutritional rickets; and
  • Potential and affordable resources of vitamin D and calcium in local communities to prevent rickets.

In addition, in cooperation with Myanmar health authorities, MOCRU/MAM proposed to:

  • Continue to screen children in Naga region and surrounding areas for rickets;
  • Treat and regularly follow up all children identified with rickets;
  • Perform blood exams and X-rays of a small patient subgroup to monitor treatment success;
  • Do community engagement to explore behaviours and raise awareness;
  • Give preventive treatment in high incidence villages for high-risk children and pregnant women.

With thanks to Frank Smithuis for text and images

Similar stories

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allowed researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.